Abstract:
Background: Reactive Arthritis (ReA) is an immune-mediated form of
spondyloarthritis, often triggered by genitourinary or gastrointestinal infections.
Current therapeutic strategies rely mainly on NSAIDs and cs-DMARDs, with
biologics reserved for refractory disease. However, limited progress has been made in
exploring novel targeted agents. Iguratimod 25 mg, an oral immunomodulatory drug
approved for rheumatoid arthritis in Asia, has demonstrated anti-inflammatory and
cytokine-suppressive properties, but evidence in ReA is scarce.
Objectives: To evaluate the clinical efficacy and cytokine-modulating effects of
Iguratimod 25 mg in patients with Reactive Arthritis compared to conventional and
biologic therapy.
